Regeneron Pharmaceuticals Soars 33% (REGN)

Shares of Regeneron Pharmaceuticals REGN have soared more than $10 in just the last few minutes on no news. The stock is now trading 33% higher at $69.23. The company had announced positive Phase III results from the pharmaceutical company's Velour drug for use in second-line metastatic colorectal cancer. The trial met its primary endpoints of improving overall survival, while most adverse side effects were mild. This was already in the market however, prior the the massive move in the last 15 minutes. One Twitter poster said that the activity may be related to a positive note out of Citigroup.